1. Home
  2. MRBK vs KROS Comparison

MRBK vs KROS Comparison

Compare MRBK & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Meridian Corporation

MRBK

Meridian Corporation

HOLD

Current Price

$20.17

Market Cap

235.5M

Sector

Finance

ML Signal

HOLD

Logo Keros Therapeutics Inc.

KROS

Keros Therapeutics Inc.

HOLD

Current Price

$10.66

Market Cap

206.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRBK
KROS
Founded
2004
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
235.5M
206.0M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
MRBK
KROS
Price
$20.17
$10.66
Analyst Decision
Strong Buy
Buy
Analyst Count
4
7
Target Price
$20.75
$21.86
AVG Volume (30 Days)
149.5K
313.0K
Earning Date
04-23-2026
05-06-2026
Dividend Yield
3.05%
N/A
EPS Growth
30.34
146.00
EPS
0.17
N/A
Revenue
$6,316,000.00
$243,864,000.00
Revenue This Year
$25.40
N/A
Revenue Next Year
$8.15
$2,751.79
P/E Ratio
$121.35
N/A
Revenue Growth
10.13
N/A
52 Week Low
$13.81
$9.69
52 Week High
$21.59
$22.55

Technical Indicators

Market Signals
Indicator
MRBK
KROS
Relative Strength Index (RSI) 59.79 46.57
Support Level $18.42 $10.14
Resistance Level $20.72 $11.55
Average True Range (ATR) 0.65 0.58
MACD 0.02 -0.06
Stochastic Oscillator 68.46 17.91

Price Performance

Historical Comparison
MRBK
KROS

About MRBK Meridian Corporation

Meridian Corp is a bank holding company based in the United States. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal and business lending and deposit services. It operates in three reportable segments, including Bank, Wealth, and Mortgage. Meridian generates maximum revenue from the Bank segment, which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans. Geographically, it operates in Pennsylvania, New Jersey, and Delaware, as well as in the Central Maryland market and southwest Florida, U.S.

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Share on Social Networks: